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Introduction
Gastric cancer is the fifth leading cause of cancer deaths 
globally.1 The prognosis of gastric cancer is poor because even 
after curative resection, advanced cancer has a high risk of re-
currence despite adjuvant chemotherapy.2-5 
To improve the response rate of chemotherapy, adenosine 
triphosphate-based chemotherapy response assays (ATP-CRAs) 
have been employed to individualize treatment.6,7 It would be 
an ideal method for choosing the most effective patient-specific 
chemotherapy agent, provided that an in vitro assay could pre-
dict the in vivo chemo-responsiveness. The most attractive fea-
ture of this assay is that it can simultaneously test the sensitivity 
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Purpose: The purpose of this pilot study was to evaluate the association between adenosine triphosphate-based chemotherapy response 
assays (ATP-CRAs) and subsets of tumor infiltrating lymphocytes (TILs) in gastric cancer.
Materials and Methods: In total, 15 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 
and January 2011. Chemotherapy response assays were performed on tumor cells from these samples using 11 chemotherapeutic 
agents, including etoposide, doxorubicin, epirubicin, mitomycin, 5-fluorouracil (5-FU), oxaliplatin, irinotecan, docetaxel, paclitaxel, meth-
otrexate, and cisplatin. TILs in the tissue samples were evaluated using antibodies specific for CD3, CD4, CD8, Foxp3, and Granzyme B.
Results: The highest cancer cell death rates were induced by etoposide (44.8%), 5-FU (43.1%), and mitomycin (39.9%). Samples 
from 10 patients who were treated with 5-FU were divided into 5-FU-sensitive and -insensitive groups according to median cell death 
rate. No difference was observed in survival between the two groups (P=0.216). Only two patients were treated with a chemothera-
peutic agent determined by an ATP-CRA and there was no significant difference in overall survival compared with that of patients treated 
with their physician’s choice of chemotherapeutic agent (P=0.105). However, a high number of CD3 TILs was a favorable prognostic 
factor (P=0.008). Pearson’s correlation analyses showed no association between cancer cell death rates in response to chemotherapeu-
tic agents and subsets of TILs.
Conclusions: Cancer cell death rates in response to specific chemotherapeutic agents were not significantly associated with the distribu-
tion of TIL subsets.
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ing assays, antitumor
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of multiple chemotherapy agents.
The distribution of tumor infiltrating lymphocytes (TILs) 
could also predict responses to neoadjuvant8-12 and adjuvant 
chemotherapies13-15 in solid cancers. TIL distribution is an in-
dependent prognostic marker for gastric cancer and other solid 
cancers.8,10,16,17 Gastric medullary carcinomas that have extensive 
infiltration of lymphocytes often show excellent prognosis.18
Thus, improving predictions for chemo-responsiveness is 
a highly desirable possibility when combining ATP-CRA re-
sults and TIL distribution. The aim of the present study was 
to explore the possibility of selecting patient-specific sensitive 
chemotherapeutic agents based on TIL-related immune micro-
environments. 
Materials and Methods
1. Patients
At Severance Hospital, Yonsei University College of Medi-
cine, from February 2007 to January 2011, 15 patients were en-
rolled for the study with histologically proven gastric cancer who 
had undergone gastric resection surgery. All data on patients’ 
characteristics and pathological features of resected tumors were 
collected by a retrospective review of a prospectively maintained 
database. No patients were treated with neoadjuvant chemo-
therapies or had histories of another primary tumor. All patients 
agreed to the chemosensitivity test of their resected tumors and 
gave informed consent. This study was approved by the Yonsei 
Institutional Review Board (4-2011-0864).
2. Adenosine triphosphate-based-based chemo-
therapy response assays 
ATP-CRAs were performed as previously described.6 
Briefly, a 0.5-cm3 sample of cancer tissue was collected, stored 
in Hank’s balanced salt solution (GIBCO BRL, Rockville, MD, 
USA) containing 100 IU/ml penicillin (Sigma, St. Louis, MO, 
USA), 100 mg/ml streptomycin (Sigma), 100 mg/ml gentamicin 
(GIBCO BRL), 2.5 mg/ml amphotericin B (GIBCO BRL), and 5% 
fetal bovine serum (GIBCO BRL), and immediately sent to the 
pathology laboratory. Tissues were washed, quantified, minced, 
and enzymatically dissociated. Cells were purified by density 
centrifugation to eliminate debris. After dilution of the separated 
tumor cells to 2×104 cells/ml, cells were seeded in triplicate in 
96-well microplates (Costar, Cambridge, MA, USA). 
In the treated groups, 100 ml of chemotherapeutic agents were 
added to the seeded cells, and 100 ml of Iscove’s modified Dul-
becco’s medium (GIBCO BRL) without chemotherapeutic agents 
were added to the untreated control groups. Samples from each 
patient were individually treated with each of the chemotherapeutic 
agents. The test drug concentrations were determined based on peak 
plasma concentrations according to previous reports: etoposide (3.57 
mg/ml), doxorubicin (1.5 mg/ml), epirubicin (1.2 mg/ml), mitomycin 
(0.2 mg/ml), 5-fluorouracil (5-FU, 10 mg/ml), oxaliplatin (2.9 mg/
ml), irinotecan (4.7 mg/ml), docetaxel (3.7 mg/ml), paclitaxel (8.5 
mg/ml), methotrexate (0.37 mg/ml), and cisplatin (2.5 mg/ml).19-21 
Three different doses (0.2-, 1-, and 5-fold) of the test drug were 
used in triplicate. Microplates were cultured for 48 hours at 37oC 
in 5% CO2. ATP levels in the cell lysates were measured us-
ing flash type luminescence measurements (Roche, Mannheim, 
Germany). Cancer cell death rates were determined as the ratio 
of ATP luminescence reduction in the treated groups compared 
to that of the untreated control.
3. Quantification of tumor infiltrating lymphocyte 
subsets
Immunohistochemical staining and quantification of TIL 
subsets was performed as previously described.16 Paraffin-
embedded gastric cancer tissue sections were serially sectioned 
at 4-mm, deparaffinized in xylene, and rehydrated in decreasing 
concentrations of ethanol. Antigen retrieval was performed in 
citrate buffer in a microwave. Endogenous peroxidase activity 
was blocked by incubating in 3% hydrogen peroxide in methanol 
for 5 minutes. Sections were incubated for 60 minutes at room 
temperature (20oC to 25oC) with primary monoclonal antibodies: 
CD3 (1:100; Lab Vision Corporation, Fremont, CA, USA), CD4 
(1:100; Novocastra, Newcastle Upon Tyne, UK), CD8 (1:100; 
Novocastra), Foxp3, (forkhead/winged helix transcription fac-
tor 3, 1:100, ab20034; Abcam, Cambridge, UK), and Granzyme 
B (1:100; Lab Vision Corporation), which were used to identify 
the following T lymphocyte subsets: total T lymphocytes, helper 
T lymphocytes, cytotoxic T lymphocytes, regulatory T cells, 
and activated cytotoxic T lymphocytes, respectively. Incuba-
tion in horseradish peroxidase-conjugated secondary antibody 
was subsequently performed, followed by development with 
diaminobenzidine and counterstaining with hematoxylin. Five 
high-power fields (×400) from each slide were selected for 
manual counting using an Olympus CX31 microscope (Olym-
pus America, Center Valley, PA, USA). The absolute number 
of lymphocytes per high-power field was determined for each 
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antibody (CD3, CD4, CD8, Foxp3, and Granzyme B). The me-
dian count number was used to divide the patients into low- and 
high-density groups.
4. Statistical analysis
Pearson’s correlation tests were performed for cancer cell 
death rates and TIL subsets. Absolute numbers of cells positive 
for each stain were dichotomized using cut-off values derived 
by the median. Survival curves were constructed using the Ka-
plan-Meier method, and the log-rank test was used to evaluate 
the significance. A statistical significance level was defined as a 
P-value of 0.05 or less. All statistical analyses were performed 
with SAS 9.2 software (SAS Institute, Cary, NC, USA).
Results
1. Clinicopathological characteristics
The clinicopathological features of 15 patients are presented 
in Table 1. Of 15 patients, 14 were male and 1 was female. The 
mean age was 58.9 years. The distribution of the stages accord-
ing to 7th American Joint Committee on Cancer classification 
included seven stage II (46.7%), six stage III (40.0%), and two 
stage IV (13.3%).
2. In vitro chemosensitivity test results
The cytotoxic effect of the chemotherapeutic agents tested 
at previously published peak plasma concentrations19-21 ranged 
from 0% to 72.7% cell death (Table 2). The highest cancer cell 
death rates were seen in cells treated with etoposide (44.8%), 
5-FU (43.1%), and mitomycin (39.9%). The rank of each 
chemotherapeutic agent among 11 agents was determined ac-
cording to that cell death rate in each patient. The most active 
chemotherapeutic agent was etoposide, with the highest chemo-
sensitivity, 60.0% (9/15) for the tested specimens. Ten patients 
who underwent 5-FU chemotherapy were categorized into 
higher- and lower-cell death rate groups based on their median 
cell death rates. The overall survival of these two groups was 
analyzed. The 5-FU-sensitive patients showed better survival, 
though the difference was not statistically significant (P=0.216; 
Fig. 1A). Among the 15 patients, only two patients were treated 
with adjuvant chemotherapeutic agents as determined by ATP-
CRAs (one with etoposide and one with cisplatin) that had 
the highest chemosensitivity results. Among the remaining 13 
patients, 8 patients were treated with 5-FU based chemothera-
peutic agents and 1 patient was treated with a docetaxel based 
chemotherapeutic agent. The other 4 patients did not received 
adjuvant chemotherapy. Fig. 1B shows the survival comparison 
of patients who were treated according to ATP-CRA results or 
who were treated with chemotherapeutic agents chosen by their 
physician (P=0.105). 
3. Subsets of tumor infiltrating lymphocytes
The median number of cells positive for CD3, CD4, CD8, 
Foxp3, and Granzyme B were 156.0, 64.7, 80.7, 15.3, and 10, 
Table 1. Clinicopathological features of patients
Variable Characteristic Patient (n=15)
Sex Male 14 (93.3)
Female 1 (6.7)
Age (yr) 58.9
Tumor location Upper 5 (33.3)
Middle 1 (6.7)
Lower 9 (60.0)
T classification* T1 1 (6.7)
T2 0 (0)
T3 8 (53.3)
T4 6 (40.0) 
N classification* N0 5 (33.3)
N1 2 (13.3)
N2 1 (6.7)
N3 7 (46.7)
M stage* M0 13 (86.7)
M1 2 (13.3)
Stage* Stage I 0 (0)
Stage II 7 (46.7)
Stage III 6 (40.0)
Stage IV 2 (13.3)
Lauren classification Intestinal 10 (66.7)
Diffuse 5 (33.3)
Lymphatic invasion Yes 10 (66.7)
No 5 (33.3)
Vascular invasion Yes 9 (60.0)
No 6 (40.0)
Neural invasion Yes 11 (73.3)
No 4 (26.7)
Values are presented as number (%) or mean only. *Classification 
according to the standard of American Joint Committee on Cancer, 
7th edition.
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respectively (Table 3). Using the median values, all cases were 
classified into low- and high-density groups for each variable and 
survival rates were compared. A higher number of total T lym-
phocytes (CD3) was a good prognostic factor (P=0.008; Fig. 1C).
Table 2. Cancer cell death rates following treatment with chemotherapeutic agents in adenosine triphosphate-based chemotherapy response 
assays
Chemo agent Mean±standard deviation Median (range) 1st rank No. Chosen for adjuvant chemotherapy
Etoposide 44.8±22.7 56.0 (3.6~72.7) 9/15 1/9
Doxorubicin 27.9±19.3 29.3 (0~70.3) 0/15
Epirubicin 24.8±17.0 21.7 (0~55.8) 0/15
Mitomycin 39.9±18.9 46.9 (2.7~65.8) 0/15
5-fluorouracil 43.1±12.8 45.7 (18.8~62.7) 2/15 0/2
Oxaliplatin 38.6±13.8 41.9 (16.4~57.1) 0/15
Irinotecan 35.0±11.5 34.8 (15.2~54.2) 2/15 0/2
Docetaxel 23.6±14.1 19.9 (0~44.0) 0/15
Paclitaxel 22.3±17.4 16.0 (0~49.3) 0/15
Methotrexate 17.8±15.7 17.1 (0~56.2) 1/15 0/1
Cisplatin 23.2±17.7 23.3 (0~53.4) 1/15 1/1
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Fig. 1. Survival analysis according to chemotherapeutic agent choice 
and tumor infiltrating lymphocytes (TILs). (A) Survival of patients 
who were treated by 5-fluorouracil (5-FU) (P=0.216). From 15 pa-
tients, 10 patients underwent 5-FU adjuvant chemotherapy. According 
to median cell death rates in adenosine triphosphate-based chemo-
therapy response assays (ATP-CRAs), patients were grouped as sensi-
tive (n=5) and insensitive (n=5) to 5-FU. (B) Survival of patients who 
were treated with therapeutic agents as determined by ATP-CRAs (n=2) 
versus those chosen by a physician (n=8) (P=0.105). (C) Survival of 
high- (n=5) and low-CD3 (n=5) patients. Of the various TIL subsets 
examined, only high numbers of CD3 TILs (total T lymphocytes) 
showed favorable prognosis (P=0.008).
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4. Association between cancer cell death rates and 
tumor infiltrating lymphocyte subsets
Pearson’s correlation tests showed no statistically significant 
association between cancer cell death rates as determined by 
ATP-CRA for each chemotherapeutic agent and the TIL subsets 
from the correlating patient (Table 4). Three pairings of che-
motherapeutic agents/count number of TIL subsets, docetaxel-
CD4, 5-FU-Granzyme B, and methotrexate-Granzyme B had 
marginal associations with correlation coefficients of -0.453, 
0.506, and 0.477, respectively, and P-values of 0.090, 0.054, and 
0.072, respectively (Fig. 2A~C). The most commonly used che-
motherapeutic agents in Korea, 5-FU and cisplatin, also showed 
no significant association with the CD3 subset, which showed 
prognostic implications in this study (Fig. 2D, E). 
Discussion
Accumulating evidence suggests that the immune microen-
vironment alters chemo-responsiveness.22,23 Previous studies on 
chemo-responsiveness used various chemotherapeutic agents 
for different types of cancer. Thus, translation of the results to 
gastric cancer treatment is challenging. For example, high post-
treatment levels of CD3 or CD8 TIL subsets in the tumor micro-
environment correlates with more robust responses to paclitaxel 
neoadjuvant chemotherapy in breast cancer.24 Additionally, the 
density of CD8 TILs affects the chemo-responsiveness to 5-FU 
in stage III colon cancer.25 Higher densities of CD3, CD8, and 
Granzyme B, but not of Foxp3 TILs at invasive margins are 
related to improved chemo-responsiveness to irinotecan- and 
platinum-based chemotherapies in metastatic colorectal cancer.26 
Furthermore, the level of regulatory T cells prior to chemother-
apy is a predictive marker for early breast cancer.27 However, 
the relationship of the immune microenvironment and chemo-
responsiveness in gastric cancer has never been studied. To ex-
plore whether cancer cell response to chemotherapeutic agents 
has any relationship with immune microenvironments, we 
investigated the association of cancer cell death rates in ATP-
CRAs and the distribution of TIL subsets within the tumor tissue 
microenvironment. However, no significant associations were 
identified.
It is unknown whether TILs cause or enhance susceptibil-
ity to chemotherapeutic agents or are simply chemosensitiv-
Table 3. Tumor infiltrating lymphocyte subsets within tumor tissues
Subset Mean*±standard deviation Median (range)
Survival 
P-value
CD3 159.0±43.0 156.0 (67~221) 0.008
CD4 68.1±18.3 64.7 (46~115.3) 0.369
CD8 85.5±37.3 80.7 (36~165.3) 0.389
Foxp3† 18.6±7.6 15.3 (9~37) 0.165
Granzyme B 13.6±10.1 10 (2.7~39.7) 0.309
*Number of cells per high-power field. †Forkhead/winged helix 
transcription factor 3.
Table 4. Pearson’s correlations between tumor infiltrating lymphocyte subsets and cell death rates in response to chemotherapeutic agents
Variable
Correlation coefficient (P-value)
CD3 CD4 CD8 Foxp3* Granzyme B
Etoposide 0.005 (0.986) 0.164 (0.560) –0.048 (0.865) 0.199 (0.478) –0.212 (0.449)
Doxorubicin 0.097 (0.730) 0.232 (0.405) 0.010 (0.973) 0.356 (0.193) –0.087 (0.758)
Epirubicin 0.392 (0.149) 0.276 (0.318) 0.156 (0.578) 0.386 (0.155) 0.014 (0.962)
Mitomycin –0.159 (0.571) 0.194 (0.489) –0.058 (0.837) 0.324 (0.239) –0.238 (0.393)
5-fluorouracil 0.356 (0.193) –0.002 (0.994) 0.255 (0.360) 0.338 (0.217) 0.506 (0.054)
Oxaliplatin 0.248 (0.373) 0.402 (0.137) –0.101 (0.721) 0.257 (0.355) –0.219 (0.433)
Irinotecan 0.285 (0.302) 0.282 (0.309) 0.135 (0.631) 0.308 (0.264) 0.138 (0.625)
Docetaxel –0.022 (0.937) –0.453 (0.090) –0.066 (0.816) 0.091 (0.747) 0.277 (0.318)
Paclitaxel –0.116 (0.693) 0.148 (0.614) –0.117 (0.691) 0.026 (0.931) 0.248 (0.393)
Methotrexate 0.238 (0.393) 0.111 (0.694) 0.365 (0.181) 0.223 (0.424) 0.477 (0.072)
Cisplatin 0.238 (0.393) –0.052 (0.853) –0.230 (0.410) 0.136 (0.630) –0.053 (0.851)
*Forkhead/winged helix transcription factor 3.
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ity markers. The current study suggests that TILs are more 
representative of susceptibility to chemotherapy rather than a 
marker of chemosensitivity. Our ATP-CRA and TIL analyses 
were separately performed using cultured cancer cells and im-
munohistochemical staining of tumor tissues. Thus, it may not 
completely and accurately represent the in situ interactive effects 
of chemotherapy on the tumor/host immune system. A subset 
of TILs in tumor microenvironments can modulate the suscep-
tibility of chemotherapy against cancer cells.9,28,29 Conversely, 
chemotherapy can enhance the efficacy of host immune func-
tions by reducing tumor burdens and enhancing tumor cell sus-
ceptibility.30 It is also known that tumor-associated antigens are 
released when chemotherapeutic agents destroy tumor cells.9 
Limitations of this study include the small number of the 
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Fig. 2. Pearson’s correlation scatter plots for cell death rates in response 
to various chemotherapeutic agents in adenosine triphosphate-based 
chemotherapy response assays and tumor infiltrating lymphocyte 
subsets for 15 patients. (A) CD4-docetaxel cell death rate (CDR). (B) 
Granzyme B-5-fluorouracil (5-FU) CDR. (C) Granzyme B-Methotrex-
ate CDR. (D) CD3-5-FU CDR. (E) CD3-cisplatin CDR. For all graphs, 
each point represents results from a single patient.
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patients, emphasizing the need for further validation of these 
observations in additional data sets; only a small portion of the 
patients were treated according to ATP-CRA results; and the 
biological mechanism underlying these observations was not 
studied. Despite these limitations, we tried to assess the associa-
tion of chemosensitivity test results and TIL subsets in gastric 
cancer. No significant association between the two suggests that 
current ATP-CRA has limitations for predicting cancer cell de-
struction, which could be affected by the immune system.
In conclusion, cancer cell death rates in response to specific 
chemotherapeutic agents had a poor association with the distri-
bution of TIL subsets. 
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